• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Malaysia·Healthcare·0101.KL
Share

TMC Life Sciences Berhad Stocks

MYR 0.45Last Updated 24.06.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

MYR 183.29M

MYR 0.45
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

TMC Life Sciences Berhad operates as an investment holding entity, specializing in the provision of healthcare services throughout Malaysia. Its primary asset is Thomson Hospital Kota Damansara (THKD), a substantial 559-bed medical facility located in Selangor. THKD delivers a comprehensive spectrum of medical specialties, including orthopedics, ear, nose, and throat (ENT) care, head and neck laser procedures, dedicated services for women and children, fertility treatments, dietetic guidance, and emergency care. The company's fertility centers offer advanced reproductive technologies such as time-lapse imaging, preimplantation genetic testing, and fertility genecode analysis, alongside expert consultancy services. Beyond its main hospital operations, TMC Life Sciences manages a network of women's clinics and fertility centers, provides laboratory and embryology services, traditional and complementary medicine, and operates pharmacy outlets. Its activities further extend to developing and marketing healthcare programs, offering multi-disciplinary tertiary care support, engaging in research and development initiatives, and undertaking property investments. Established in 1994 and based in Petaling Jaya, Malaysia, the company is a subsidiary of Sasteria (M) Pte. Ltd.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 15:25

Three small-cap companies in the AI sector: They could benefit from OpenAI's IPO

24.06.2026 15:11

A Morning in New York: High Tech in a Period of Turbulence

24.06.2026 14:57

Shares of biotech company Boundless soared 90% amid a market sell-off. What's the reason?

24.06.2026 14:15

Nasdaq 100 companies lost $1.3 trillion in market capitalization in two days

24.06.2026 13:44

Brent crude oil prices fell below $76—a four-month low

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026